These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32519166)

  • 41. Stroke prevention and guideline adherent antithrombotic treatment in elderly patients with atrial fibrillation: A real-world experience.
    Gorczyca I; Jelonek O; Michalska A; Chrapek M; Wałek P; Wożakowska-Kapłon B
    Medicine (Baltimore); 2020 Jul; 99(29):e21209. PubMed ID: 32702889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
    Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
    BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
    Ruigómez A; Vora P; Balabanova Y; Brobert G; Roberts L; Fatoba S; Fernandez O; García Rodríguez LA
    BMJ Open; 2019 Oct; 9(10):e031342. PubMed ID: 31630107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF).
    Sun Y; Zhu J; Ma C; Liu S; Yang Y; Hu D
    Cardiovasc Ther; 2019; 2019():7372129. PubMed ID: 31772614
    [No Abstract]   [Full Text] [Related]  

  • 48. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temporal Trends in Pharmacological Stroke Prevention in Patients with Acute Ischemic Stroke and Known Atrial Fibrillation.
    Hellwig S; Grittner U; Herm J; Ruschmann R; Konieczny M; Endres M; Haeusler KG
    J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105266. PubMed ID: 32992191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
    Lasek-Bal A; Urbanek T; Gierek D
    Int Angiol; 2015 Dec; 34(6):552-61. PubMed ID: 25410296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry.
    Gullón A; Suárez C; Díez-Manglano J; Formiga F; Cepeda JM; Pose A; Camafort M; Castiella J; Rovira E; Mostaza JM;
    Med Clin (Barc); 2017 Mar; 148(5):204-210. PubMed ID: 27993408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Komatsubara I; Kusachi S
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):118-126. PubMed ID: 28170360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 60. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.